A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

Summary

The study is an open-label, Tolvaptan-controlled Phase I study to evaluate the safety, tolerability, PK/PD profile and efficacy of HRS-9057 in the treatment of heart failure with volume overload. A total of 24 subjects who experience volume overload due to heart failure despite diuretic treatment will be enrolled in the study and receive HRS-9057 injection or Tolvaptan tablets.

Timeline

Start

2024-08-16

Primary completion

2025-10-29

Completion

2025-10-29

Drugs

Indications